Blueprint Medicines (BPMC)
(Delayed Data from NSDQ)
$116.32 USD
+4.62 (4.14%)
Updated Jul 8, 2024 04:00 PM ET
After-Market: $116.30 -0.02 (-0.02%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth C Momentum F VGM
Price, Consensus and EPS Surprise
BPMC 116.32 +4.62(4.14%)
Will BPMC be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BPMC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BPMC
Zacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand
PetIQ (PETQ) Gears Up to Report Q1 Earnings: What's in Store?
BPMC: What are Zacks experts saying now?
Zacks Private Portfolio Services
5 Biotech Stocks Worth Adding to Your Portfolio in 2024
Blueprint (BPMC) Q1 Earnings and Revenues Beat, Stock Rises
Zoetis (ZTS) Q1 Earnings and Revenues Surpass Estimates
Other News for BPMC
Expert Ratings For Blueprint Medicines
Blueprint Medicines: A Strong Buy on Robust Pipeline and Strategic Growth Opportunities
Blueprint Medicines management to meet with JMP Securities
Blueprint Medicines management to meet with JMP Securities
Blueprint Medicines management to meet with JMP Securities